Seneca Therapeutics was found by Dr. Paul Hallenbeck to develop the Seneca Valley Virus (“SVV-001”), a best in class oncolytic virus. SVV-001 is already in Phase I/II and has a clinical safety record in humans. SVV-001 binds to the TEM8 receptor which is common in many solid tumors like breast cancer, lung cancer and neuroendocrine tumors. SVV-001 is also being considered as a viral vector for gene therapy targeting the TEM8 receptor in solid tumors.
View Top Employees from Seneca Therapeutics, Inc.| Website | http://www.senecatherapeutics.com |
| Revenue | $2 million |
| Employees | 10 (4 on RocketReach) |
| Founded | 2018 |
| Industry | Biotechnology Research, Business Services General, Drug Discovery, Business Services, Biotechnology |
| Competitors | Batu Biologics, Inc., Bellicum Pharmaceuticals, Inc., Lixte Biotechnology Holdings, Inc., Moleculin Biotech, Inc., Revitope |
| SIC | SIC Code 873 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 541714 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 5417 Companies, NAICS Code 54171 Companies |
Looking for a particular Seneca Therapeutics, Inc. employee's phone or email?
Seneca Therapeutics, Inc. Questions
The Seneca Therapeutics, Inc. annual revenue was $2 million in 2024.
Paul Hallenbeck is the Founder and Chief Executive Officer of Seneca Therapeutics, Inc..
4 people are employed at Seneca Therapeutics, Inc..
Seneca Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
The NAICS codes for Seneca Therapeutics, Inc. are [541714, 54, 541, 5417, 54171].
The SIC codes for Seneca Therapeutics, Inc. are [873, 87].
Top Seneca Therapeutics, Inc. Employees
-
45+
-
35+
-
55+
-
ViewMark Kerschner
Board Member at Seneca Therapeutics, Inc.
Philadelphia, Pennsylvania, United States32
Related Companies
